EGR1 Nuclear Condensates Promote Renal Cyst Development in Polycystic Kidney Disease

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is marked by aberrant cell proliferation driven by cAMP-PKA and MAPK signaling pathways. EGR1, a transcription factor directly activated by the above two pathways, is critical in the over-proliferation of tumor cells, which share similarities with cystic epithelial cells in ADPKD. This study utilized in vitro cell models, three-dimensional (3D) cyst model, embryonic renal cystic model, and PKD mouse model to clarify the role of EGR1 in cyst development of ADPKD. We found the high expression and nuclear condensates of EGR1 in human ADPKD renal cyst epithelial cells and PKD mouse kidney tissue. Pharmacological inhibition of EGR1 retarded cyst enlargement in in vitro, ex vivo, and in vivo ADPKD models. Furthermore, EGR1 formed nuclear condensates with YAP1 and CBP via phase separation, leading to EGR1-specific transcriptional activation and upregulation of cell-cycle-related genes (e.g., CCND1, CCNE1, and CDK4/6), thus promoting abnormal renal cystic epithelial cell proliferation. Disruption of EGR1 phase separation significantly alleviated cyst growth in the forskolin-induced 3D spheroid model of mIMCD3 cells and MDCK cyst model. These findings demonstrate that phase separation-mediated EGR1 condensates facilitate renal cyst development in ADPKD.

Keywords

ADPKD / EGR1 / cyst development / condensate / phase separation

References

[1] A. Alam, E. Cornec-Le Gall, and R. D. Perrone, “What Is Autosomal Dominant Polycystic Kidney Disease?,” JAMA 329, no. 13 (2023): 1128, https://doi.org/10.1001/jama.2023.2161.

[2] A. Casarella, R. Nicotera, M. T. Zicarelli, et al., “Autosomic Dominant Polycystic Kidney Disease and Metformin: Old Knowledge and New Insights on Retarding Progression of Chronic Kidney Disease,” Medicinal Research Reviews 42, no. 1 (2022): 629–640, https://doi.org/10.1002/med.21850.

[3] C. Zoccali, P. B. Mark, P. Sarafidis, et al., “Diagnosis of Cardiovascular Disease in Patients With Chronic Kidney Disease,” Nature Reviews Nephrology 19, no. 11 (2023): 733–746, https://doi.org/10.1038/s41581-023-00747-4.

[4] J. X. Zhou and V. E. Torres, “Drug Repurposing in Autosomal Dominant Polycystic Kidney Disease,” Kidney International 103, no. 5 (2023): 859–871, https://doi.org/10.1016/j.kint.2023.02.010.

[5] F. J. Borrego Utiel and M. Espinosa Hernández, “How to Estimate Kidney Growth in Patients With Autosomal Dominant Polycystic Kidney Disease,” Journal of the American Society of Nephrology 34, no. 6 (2023): 944–950, https://doi.org/10.1681/ASN.0000000000000130.

[6] T. Bais, R. T. Gansevoort, and E. Meijer, “Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease,” Drugs 82, no. 10 (2022): 1095–1115, https://doi.org/10.1007/s40265-022-01745-9.

[7] I. Capuano, P. Buonanno, E. Riccio, M. Amicone, and A. Pisani, “Therapeutic Advances in ADPKD: The Future Awaits,” Journal of Nephrology 35, no. 2 (2022): 397–415, https://doi.org/10.1007/s40620-021-01062-6.

[8] M. Liu, C. Zhang, X. Gong, et al., “Kidney Organoid Models Reveal Cilium-Autophagy Metabolic Axis as a Therapeutic Target for PKD both In Vitro and In Vivo,” Cell Stem Cell 31, no. 1 (2024): 52–70.e8, https://doi.org/10.1016/j.stem.2023.12.003.

[9] L. Luo, S. Roy, L. Li, and M. Ma, “Polycystic Kidney Disease: Novel Insights Into Polycystin Function,” Trends in Molecular Medicine 29, no. 4 (2023): 268–281, https://doi.org/10.1016/j.molmed.2023.01.005.

[10] O. Esarte Palomero, M. Larmore, and P. G. De Caen, “Polycystin Channel Complexes,” Annual Review of Physiology 85 (2023): 425–448, https://doi.org/10.1146/annurev-physiol-031522-084334.

[11] L. Onuchic, V. Padovano, G. Schena, et al., “The C-terminal Tail of Polycystin-1 Suppresses Cystic Disease in a Mitochondrial Enzyme-Dependent Fashion,” Nature Communications 14, no. 1 (2023): 1790, https://doi.org/10.1038/s41467-023-37449-1.

[12] Y. R. Mehta, S. A. Lewis, K. T. Leo, et al., ““ADPKD-Omics”: Determinants of Cyclic AMP Levels in Renal Epithelial Cells,” Kidney International 101, no. 1 (2022): 47–62, https://doi.org/10.1016/j.kint.2021.10.014.

[13] C. Huynh, J. Ryu, J. Lee, A. Inoki, and K. Inoki, “Nutrient-Sensing mTORC1 and AMPK Pathways in Chronic Kidney Diseases,” Nature Reviews Nephrology 19, no. 2 (2023): 102–122, https://doi.org/10.1038/s41581-022-00648-y.

[14] V. J. Hwang, X. Zhou, X. Chen, et al., “Anticystogenic Activity of a Small Molecule PAK4 Inhibitor May be a Novel Treatment for Autosomal Dominant Polycystic Kidney Disease,” Kidney International 92, no. 4 (2017): 922–933, https://doi.org/10.1016/j.kint.2017.03.031.

[15] L. Su, L. Liu, Y. Jia, et al., “Ganoderma Triterpenes Retard Renal Cyst Development by Downregulating Ras/MAPK Signaling and Promoting Cell Differentiation,” Kidney International 92, no. 6 (2017): 1404–1418, https://doi.org/10.1016/j.kint.2017.04.013.

[16] M. Wei, X. Gu, H. Li, et al., “EGR1 is Crucial for the Chlorogenic Acid–Provided Promotion on Liver Regeneration and Repair After APAP-Induced Liver Injury,” Cell Biology and Toxicology 39, no. 6 (2023): 2685–2707, https://doi.org/10.1007/s10565-023-09795-9.

[17] J.-W. Chen, M.-J. Huang, X.-N. Chen, et al., “Transient Upregulation of EGR1 Signaling Enhances Kidney Repair by Activating SOX9 + Renal Tubular Cells,” Theranostics 12, no. 12 (2022): 5434–5450, https://doi.org/10.7150/thno.73426.

[18] D. Xiao, D. Chinnappan, R. Pestell, C. Albanese, and H. C. Weber, “Bombesin Regulates Cyclin D1 Expression Through the Early Growth Response Protein Egr-1 in Prostate Cancer Cells,” Cancer Research 65, no. 21 (2005): 9934–9942, https://doi.org/10.1158/0008-5472.CAN-05-1830.

[19] H. Yao, X. Chen, T. Wang, et al., “A MYC-Controlled Redox Switch Protects B Lymphoma Cells From EGR1-Dependent Apoptosis,” Cell Reports 42, no. 8 (2023): 112961, https://doi.org/10.1016/j.celrep.2023.112961.

[20] J. Zhao, H. Li, and M. Yuan, “EGR1 Promotes Stemness and Predicts a Poor Outcome of Uterine Cervical Cancer by Inducing SOX9 Expression,” Genes & Genomics 43, no. 5 (2021): 459–470, https://doi.org/10.1007/s13258-021-01064-5.

[21] Z. Ma, X. Gao, Y. Shuai, et al., “EGR1-Mediated Linc01503 Promotes Cell Cycle Progression and Tumorigenesis in Gastric Cancer,” Cell Proliferation 54, no. 1 (2021): e12922, https://doi.org/10.1111/cpr.12922.

[22] M. Pan, M. Luo, L. Liu, et al., “EGR1 Suppresses HCC Growth and Aerobic Glycolysis by Transcriptionally Downregulating PFKL,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 35, https://doi.org/10.1186/s13046-024-02957-5.

[23] Y. Jin, C. Wang, B. Zhang, et al., “Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer,” International Journal of Biological Sciences 20, no. 4 (2024): 1314–1331, https://doi.org/10.7150/ijbs.90598.

[24] L. Zhang, J. Elkahal, T. Wang, et al., “EGR1 Regulates Regenerative Senescence and Cardiac Repair,” Nature Cardiovascular Research 3, no. 8 (2024): 915–932, https://doi.org/10.1038/s44161-024-00493-1.

[25] D.-G. Chen, B. Zhu, S.-Q. Lv, et al., “Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter,” Journal of Experimental & Clinical Cancer Research 36, no. 1 (2017): 186, https://doi.org/10.1186/s13046-017-0656-4.

[26] H.-T. Liu, S. Liu, L. Liu, R.-R. Ma, and P. Gao, “EGR1-Mediated Transcription of lncRNA-HNF1A-AS1 Promotes Cell-Cycle Progression in Gastric Cancer,” Cancer Research 78, no. 20 (2018): 5877–5890, https://doi.org/10.1158/0008-5472.CAN-18-1011.

[27] P.-L. Kuo, Y.-H. Chen, T.-C. Chen, K.-H. Shen, and Y.-L. Hsu, “CXCL5/ENA78 Increased Cell Migration and Epithelial-to-Mesenchymal Transition of Hormone-Independent Prostate Cancer by Early Growth Response-1/Snail Signaling Pathway,” Journal of Cellular Physiology 226, no. 5 (2011): 1224–1231, https://doi.org/10.1002/jcp.22445.

[28] E. Jung, S. Ou, S. S. Ahn, H. Yeo, Y. H. Lee, and S. Y. Shin, “The JNK-EGR1 Signaling Axis Promotes TNF-α-Induced Endothelial Differentiation of Human Mesenchymal Stem Cells via VEGFR2 Expression,” Cell Death & Differentiation 30, no. 2 (2023): 356–368, https://doi.org/10.1038/s41418-022-01088-8.

[29] L. Yu, J. Zhou, G. Zhang, et al., “cAMP/PKA/EGR1 Signaling Mediates the Molecular Mechanism of Ethanol-induced Inhibition of Placental 11β-HSD2 Expression,” Toxicology and Applied Pharmacology 352 (2018): 77–86, https://doi.org/10.1016/j.taap.2018.05.029.

[30] E. R. Simo-Cheyou, V. Youreva, and A. K. Srivastava, “cAMP Attenuates Angiotensin-II-Induced Egr-1 Expression via PKA-Dependent Signaling Pathway in Vascular Smooth Muscle Cells,” Canadian Journal of Physiology and Pharmacology 95, no. 8 (2017): 928–937, https://doi.org/10.1139/cjpp-2017-0035.

[31] M. J. Livingston, M. Zhang, S.-H. Kwon, et al., “Autophagy Activates EGR1 via MAPK/ERK to Induce FGF2 in Renal Tubular Cells for Fibroblast Activation and Fibrosis During Maladaptive Kidney Repair,” Autophagy 20, no. 5 (2023): 1032–1053.

[32] J. Shan, E. Dudenhausen, and M. S. Kilberg, “Induction of Early Growth Response Gene 1 (EGR1) by Endoplasmic Reticulum Stress Is Mediated by the Extracellular Regulated Kinase (ERK) Arm of the MAPK Pathways,” Biochimica Et Biophysica Acta (BBA)—Molecular Cell Research 1866, no. 3 (2019): 371–381, https://doi.org/10.1016/j.bbamcr.2018.09.009.

[33] N. Charolidi, G. Pirianov, E. Torsney, et al., “Pioglitazone Identifies a New Target for Aneurysm Treatment: Role of Egr1 in an Experimental Murine Model of Aortic Aneurysm,” Journal of Vascular Research 52, no. 2 (2015): 81–93, https://doi.org/10.1159/000430986.

[34] J. He, S. Zhang, Z. Qiu, et al., “Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1–Deficient Polycystic Kidney Disease in Animal Model,” Journal of the American Society of Nephrology 32, no. 9 (2021): 2159–2174, https://doi.org/10.1681/ASN.2020111560.

[35] Y. Muto, E. E. Dixon, Y. Yoshimura, et al., “Defining Cellular Complexity in Human Autosomal Dominant Polycystic Kidney Disease by Multimodal Single Cell Analysis,” Nature Communications 13, no. 1 (2022): 6497, https://doi.org/10.1038/s41467-022-34255-z.

[36] P. R. Banerjee, A. S. Holehouse, R. Kriwacki, et al., “Dissecting the Biophysics and Biology of Intrinsically Disordered Proteins,” Trends in Biochemical Sciences 49, no. 2 (2024): 101–104, https://doi.org/10.1016/j.tibs.2023.10.002.

[37] E. R. Weikum, X. Liu, and E. A. Ortlund, “The Nuclear Receptor Superfamily: A Structural Perspective,” Protein Science 27, no. 11 (2018): 1876–1892, https://doi.org/10.1002/pro.3496.

[38] B. R. Sabari, A. Dall'Agnese, A. Boija, et al., “Coactivator Condensation at Super-Enhancers Links Phase Separation and Gene Control,” Science 361, no. 6400 (2018): eaar3958, https://doi.org/10.1126/science.aar3958.

[39] E. Havis and D. Duprez, “EGR1 Transcription Factor Is a Multifaceted Regulator of Matrix Production in Tendons and Other Connective Tissues,” International Journal of Molecular Sciences 21, no. 5 (2020): 1664, https://doi.org/10.3390/ijms21051664.

[40] W. Wang, D. Li, Q. Xu, et al., “G-Quadruplexes Promote the Motility in MAZ Phase-Separated Condensates to Activate CCND1 Expression and Contribute to Hepatocarcinogenesis,” Nature Communications 15, no. 1 (2024): 1045, https://doi.org/10.1038/s41467-024-45353-5.

[41] P.-Y. Shih, Y.-L. Fang, S. Shankar, et al., “Phase Separation and Zinc-Induced Transition Modulate Synaptic Distribution and Association of Autism-Linked CTTNBP2 and SHANK3,” Nature Communications 13, no. 1 (2022): 2664, https://doi.org/10.1038/s41467-022-30353-0.

[42] T. Seeger-Nukpezah, D. M. Geynisman, A. S. Nikonova, T. Benzing, and E. A. Golemis, “The Hallmarks of Cancer: Relevance to the Pathogenesis of Polycystic Kidney Disease,” Nature Reviews Nephrology 11, no. 9 (2015): 515–534, https://doi.org/10.1038/nrneph.2015.46.

[43] E. S. Knudsen, V. Kumarasamy, R. Nambiar, et al., “CDK/Cyclin Dependencies Define Extreme Cancer Cell-Cycle Heterogeneity and Collateral Vulnerabilities,” Cell Reports 38, no. 9 (2022): 110448, https://doi.org/10.1016/j.celrep.2022.110448.

[44] J. Yu, I. De Belle, H. Liang, and E. D. Adamson, “Coactivating Factors p300 and CBP Are Transcriptionally Crossregulated by Egr1 in Prostate Cells, Leading to Divergent Responses,” Molecular Cell 15, no. 1 (2004): 83–94, https://doi.org/10.1016/j.molcel.2004.06.030.

[45] J. Yu, A. Zhuang, X. Gu, et al., “Nuclear PD-L1 Promotes EGR1-Mediated Angiogenesis and Accelerates Tumorigenesis,” Cell Discovery 9, no. 1 (2023): 33, https://doi.org/10.1038/s41421-023-00521-7.

[46] Y. Wang, C. Qin, B. Zhao, et al., “EGR1 Induces EMT in Pancreatic Cancer via a P300/SNAI2 Pathway,” Journal of Translational Medicine 21, no. 1 (2023): 201, https://doi.org/10.1186/s12967-023-04043-4.

[47] C. Desterke, A. Bennaceur-Griscelli, and A. G. Turhan, “EGR1 Dysregulation Defines an Inflammatory and Leukemic Program in Cell Trajectory of Human-Aged Hematopoietic Stem Cells (HSC),” Stem Cell Research & Therapy 12, no. 1 (2021): 419, https://doi.org/10.1186/s13287-021-02498-0.

[48] H. Nagarajan and U. Vetrivel, “Deciphering the Structural and Functional Impact of Missense Mutations in Egr1-DNA Interacting Interface: An Integrative Computational Approach,” Journal of Biomolecular Structure and Dynamics 40, no. 22 (2022): 11758–11770, https://doi.org/10.1080/07391102.2021.1965030.

[49] X. Lei, Q. Xu, C. Li, et al., “Egr1 Confers Protection Against Acetaminophen‑Induced Hepatotoxicity via Transcriptional Upregulating of Acaa2,” International Journal of Biological Sciences 18, no. 9 (2022): 3800–3817, https://doi.org/10.7150/ijbs.71781.

[50] H. K. Shirnekhi, B. Chandra, and R. W. Kriwacki, “Dissolving Fusion Oncoprotein Condensates to Reverse Aberrant Gene Expression,” Cancer Research 83, no. 20 (2023): 3324–3326, https://doi.org/10.1158/0008-5472.CAN-23-2769.

[51] H. Lyons, R. T. Veettil, P. Pradhan, et al., “Functional Partitioning of Transcriptional Regulators by Patterned Charge Blocks,” Cell 186, no. 2 (2023): 327–345.e28, https://doi.org/10.1016/j.cell.2022.12.013.

[52] Y. J. Kim, M. Lee, Y.-T. Lee, et al., “Light-Activated Macromolecular Phase Separation Modulates Transcription by Reconfiguring Chromatin Interactions,” Science Advances, no. 13 (2023): eadg1123, https://doi.org/10.1126/sciadv.adg1123.

[53] M. Du, S. H. Stitzinger, J.-H. Spille, et al., “Direct Observation of a Condensate Effect on Super-Enhancer Controlled Gene Bursting,” Cell 187, no. 2 (2024): 331–344.e17, https://doi.org/10.1016/j.cell.2023.12.005.

[54] A. R. Subramanya and C. R. Boyd-Shiwarski, “Molecular Crowding: Physiologic Sensing and Control,” Annual Review of Physiology 86 (2024): 429–452, https://doi.org/10.1146/annurev-physiol-042222-025920.

[55] G. Seydoux, M. Zhang, J. D. Forman-Kay, B. Mcstay, K. F. Liu, and P. Li, “Transitions in the Framework of Condensate Biology,” Molecular Cell 83, no. 7 (2023): 1016–1021, https://doi.org/10.1016/j.molcel.2023.03.014.

[56] I. A. Klein, A. Boija, L. K. Afeyan, et al., “Partitioning of Cancer Therapeutics in Nuclear Condensates,” Science 368, no. 6497 (2020): 1386–1392, https://doi.org/10.1126/science.aaz4427.

[57] K. Shrinivas, B. R. Sabari, E. L. Coffey, et al., “Enhancer Features That Drive Formation of Transcriptional Condensates,” Molecular Cell 75, no. 3 (2019): 549–561.e7, https://doi.org/10.1016/j.molcel.2019.07.009.

[58] S. Alberti, A. Gladfelter, and T. Mittag, “Considerations and Challenges in Studying Liquid–Liquid Phase Separation and Biomolecular Condensates,” Cell 176, no. 3 (2019): 419–434, https://doi.org/10.1016/j.cell.2018.12.035.

[59] Y. Lu, Y. Sun, Z. Liu, et al., “Activation of NRF2 Ameliorates Oxidative Stress and Cystogenesis in Autosomal Dominant Polycystic Kidney Disease,” Science Translational Medicine 12, no. 554 (2020): eaba3613, https://doi.org/10.1126/scitranslmed.aba3613.

[60] A. Boija, I. A. Klein, B. R. Sabari, et al., “Transcription Factors Activate Genes Through the Phase-Separation Capacity of Their Activation Domains,” Cell 175, no. 7 (2018): 1842–1855.e16, https://doi.org/10.1016/j.cell.2018.10.042.

[61] W.-A. Whyte, D.-A. Orlando, D. Hnisz, et al., “Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes,” Cell 153, no. 2 (2013): 307–319, https://doi.org/10.1016/j.cell.2013.03.035.

[62] X. Liu, Y. Ye, L. Zhu, et al., “Niche Stiffness Sustains Cancer Stemness via TAZ and NANOG Phase Separation,” Nature Communications 14, no. 1 (2023): 238, https://doi.org/10.1038/s41467-023-35856-y.

[63] J. M. Franklin, Z. M. Wu, and K. L. Guan, “Insights Into Recent Findings and Clinical Application of YAP and TAZ in Cancer,” Nature Reviews Cancer 23, no. 8 (2023): 512–525, https://doi.org/10.1038/s41568-023-00579-1.

[64] M. Pandya, G. Gopinathan, C. Tillberg, J. Wang, X. Luan, and T. G. H. Diekwisch, “The Hippo Pathway Effectors YAP/TAZ Are Essential for Mineralized Tissue Homeostasis in the Alveolar Bone/Periodontal Complex,” Journal of Developmental Biology 10, no. 1 (2022): 14, https://doi.org/10.3390/jdb10010014.

[65] Q. Liu, J. Li, W. Zhang, et al., “Glycogen Accumulation and Phase Separation Drives Liver Tumor Initiation,” Cell 184, no. 22 (2021): 5559–5576.e19, https://doi.org/10.1016/j.cell.2021.10.001.

[66] F. Zanconato, G. Battilana, M. Forcato, et al., “Transcriptional Addiction in Cancer Cells Is Mediated by YAP/TAZ Through BRD4,” Nature Medicine 24, no. 10 (2018): 1599–1610, https://doi.org/10.1038/s41591-018-0158-8.

[67] D. Cai, D. Feliciano, P. Dong, et al., “Phase Separation of YAP Reorganizes Genome Topology for Long-Term YAP Target Gene Expression,” Nature Cell Biology 21, no. 12 (2019): 1578–1589, https://doi.org/10.1038/s41556-019-0433-z.

[68] Y. Lu, T. Wu, O. Gutman, et al., “Phase Separation of TAZ Compartmentalizes the Transcription Machinery to Promote Gene Expression,” Nature Cell Biology 22, no. 4 (2020): 453–464, https://doi.org/10.1038/s41556-020-0485-0.

[69] M. Zagurovskaya, M. M. Shareef, A. Das, et al., “EGR-1 Forms a Complex With YAP-1 and Upregulates Bax Expression in Irradiated Prostate Carcinoma Cells,” Oncogene 28, no. 8 (2009): 1121–1131, https://doi.org/10.1038/onc.2008.461.

[70] E. S. Silverman, J. Du, A. J. Williams, R. Wadgaonkar, J. M. Drazen, and T. Collins, “cAMP-Response-Element-Binding-Protein-Binding Protein (CBP) and p300 Are Transcriptional Co-Activators of Early Growth Response Factor-1 (Egr-1),” Biochemical Journal 336 (1998): 183–189, https://doi.org/10.1042/bj3360183.

[71] J. Wang, H. Yu, Q. Ma, et al., “Phase Separation of OCT4 Controls TAD Reorganization to Promote Cell Fate Transitions,” Cell Stem Cell 28, no. 10 (2021): 1868–1883.e11, https://doi.org/10.1016/j.stem.2021.04.023.

[72] Z. Li, L. Luo, W. Yu, et al., “PPARγ Phase Separates With RXRα at PPREs to Regulate Target Gene Expression,” Cell Discovery 8, no. 1 (2022), https://doi.org/10.1038/s41421-022-00388-0.

[73] C. Li, X. Li, Z. Deng, et al., “EGR1 and EGR2 Positively Regulate Plant ABA Signaling by Modulating the Phosphorylation of SnRK2.2,” New Phytologist 241, no. 4 (2024): 1492–1509, https://doi.org/10.1111/nph.19458.

[74] X. Huang, S. Chen, W. Li, et al., “ROS Regulated Reversible Protein Phase Separation Synchronizes Plant Flowering,” Nature Chemical Biology 17, no. 5 (2021): 549–557, https://doi.org/10.1038/s41589-021-00739-0.

[75] A. Ruiz De Sabando, C. Wang, Y. He, et al., “ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer,” Molecular Cancer Therapeutics 15, no. 1 (2016): 72–83, https://doi.org/10.1158/1535-7163.MCT-15-0600.

[76] X. Cao, R. Mahendran, G. R. Guy, and Y. H. Tan, “Protein Phosphatase Inhibitors Induce the Sustained Expression of the Egr-1 Gene and the Hyperphosphorylation of Its Gene Product,” Journal of Biological Chemistry 267, no. 18 (1992): 12991–12997, https://doi.org/10.1016/S0021-9258(18)42372-1.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.